Squarepoint Ops LLC Takes Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Squarepoint Ops LLC purchased a new stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 26,808 shares of the company's stock, valued at approximately $530,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Lazard Asset Management LLC acquired a new position in shares of Kiniksa Pharmaceuticals in the 4th quarter valued at about $61,000. KLP Kapitalforvaltning AS acquired a new position in Kiniksa Pharmaceuticals during the 4th quarter valued at about $158,000. Bellevue Group AG acquired a new position in Kiniksa Pharmaceuticals during the 4th quarter valued at about $160,000. Tower Research Capital LLC TRC boosted its stake in Kiniksa Pharmaceuticals by 117.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company's stock valued at $168,000 after purchasing an additional 4,575 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Kiniksa Pharmaceuticals by 12.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company's stock valued at $174,000 after purchasing an additional 1,004 shares during the period. 53.95% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals Stock Performance

Shares of NASDAQ:KNSA traded up $0.64 during trading on Thursday, reaching $29.52. The company had a trading volume of 1,058,697 shares, compared to its average volume of 499,914. The firm's fifty day moving average is $23.96 and its 200 day moving average is $21.78. The firm has a market capitalization of $2.15 billion, a PE ratio of -210.84 and a beta of 0.06. Kiniksa Pharmaceuticals, Ltd. has a twelve month low of $17.38 and a twelve month high of $29.75.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, topping analysts' consensus estimates of $0.02 by $0.09. The company had revenue of $137.79 million during the quarter, compared to analyst estimates of $128.35 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business's revenue for the quarter was up 72.5% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.25) EPS. Equities analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Mark Ragosa sold 18,299 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $28.80, for a total value of $527,011.20. Following the sale, the chief financial officer now directly owns 27,009 shares in the company, valued at $777,859.20. The trade was a 40.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Ross Moat sold 27,594 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $29.02, for a total transaction of $800,777.88. Following the completion of the sale, the insider now owns 9,415 shares in the company, valued at $273,223.30. The trade was a 74.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 391,014 shares of company stock worth $10,101,143 in the last ninety days. 54.57% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

KNSA has been the subject of a number of analyst reports. Jefferies Financial Group boosted their target price on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the company a "buy" rating in a research note on Tuesday, April 29th. Wedbush reissued an "outperform" rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research note on Wednesday, April 16th. Finally, Citigroup initiated coverage on shares of Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They set a "buy" rating and a $40.00 target price for the company. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Kiniksa Pharmaceuticals presently has an average rating of "Buy" and a consensus target price of $38.80.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.